Please login to the form below

Not currently logged in
Email:
Password:

Ariad to commence ponatinib trial for leukaemias

Ariad has announced that it will commence the phase II clinical trial of ponatinib in patients with certain types of leukaemia

Specialising in developing new, breakthrough therapies with the potential to transform the lives of patients with difficult-to-treat cancers, the Massachusetts-based company, Ariad Pharmaceuticals, has announced the initiation of the pivotal phase II clinical trial of its investigational pan-BCR-ABL inhibitor, ponatinib (previously known as AP24534), in patients with resistant or intolerant chronic myeloid leukaemia (CML) and Philadelphia positive acute lymphoblastic leukaemia (Ph+ ALL).

The PACE (Ponatinib Ph+ ALL and CML Evaluation) trial is designed to provide definitive clinical data for regulatory approval of ponatinib in this setting. Ponatinib has been granted orphan drug status in both the US and Europe for the treatment of CML and Ph+ ALL.

"The start of the pivotal PACE trial represents an important step in the development of our second molecularly targeted cancer therapy," said Harvey J Berger, Ariad's MD, chairman and chief executive officer.

"With the strong clinical evidence observed to date of haematologic, cytogenetic and molecular anti-leukaemia activity of ponatinib in heavily pre-treated patients with CML, including those patients with the T315I mutation for whom no current treatments are available, we are highly optimistic about the likelihood of success for ponatinib in this registration trial. We also believe that the time to full patient enrolment in this study and to potential regulatory approval of ponatinib will be swift."

20th September 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...
Health knowledge: Why is it so important?
Health knowledge plays an important role in population health, but by itself is rarely enough to prompt a change in the behaviours that cause the risks....
Personas: a top tool for personalising pharma marketing campaigns
Healthcare customers are calling for greater personalisation in care from providers. Here, we explain why personas are the top tool for ensuring your brand meets this need efficiently and effectively....

Infographics